Navigation Links
Muscle mass: Scientists identify novel mode of transcriptional regulation during myogenesis
Date:8/17/2007

In an upcoming issue of G&D, Drs. Maria Divina Deato and Robert Tjian (HHMI, UC Berkeley) reveal that the formation of an alternative transcriptional core promoter complex directs cell-type specific differentiation during myogenesis. The article uncovers a whole new level of transcriptional control of terminal cell differentiation, and will be published online ahead of its September 1 print date at www.genesdev.org.

For nearly 30 years, we have assumed that the basal transcription machinery, particularly the highly conserved TBP and TFIID complex, would be invariant and universal for all cell types in eukaryotes. It seems that this simplistic model will need to be revised with significant implications for mechanisms controlling multi-cellular differentiation, explains Dr. Tjian.

Skeletal muscle differentiation, or myogenesis, involves a multi-step transition from muscle precursor cells (myoblasts) to myotubes that ultimately comprise the contractile myofibers of the muscle tissue. Drs. Deato and Tjian show that during myogenesis, a component of the canonical transcription initiation machinery a multi-subunit transcription factor called TFIID is disassembled and replaced with an alternative core promoter recognition complex. The researchers determined that this alternative complex contains both TAF3 and TRF3, and is required for successful myogenesis.


'/>"/>
Contact: Heather Cosel
coselpie@cshl.edu
Cold Spring Harbor Laboratory
Source:Eurekalert

Page: 1

Related biology news :

1. Muscle-targeted gene therapy reverses rare muscular dystrophy in mice
2. X-Ray Beams And Fruit Fly Flight Simulator Aid Scientists View Of Muscle Power
3. Heart repair gets new muscle
4. Young Blood Revives Aging Muscles, Stanford Researchers Find
5. Small worm yields big clue on muscle receptor action
6. New complete muscle grown in the lab
7. Spiders help scientists discover how muscles relax
8. Cant serve an ace? Could be muscle fatigue
9. Lance Armstrong through a physiological lens: hard training boosts muscle power 8%
10. Muscle repair: Making a good system better, faster; implications for aging, disease
11. Gene therapy for muscular dystrophy fixes frail muscle cells in animal model, Stanford study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: